Macugen meets Phase II CRVO endpoint

OSI (OSIP) said Macugen pegaptanib met the primary endpoint of improved visual acuity at week 30 in a Phase II trial to treat macular edema due to central retinal vein occlusion (CRVO). In the U.S. an...